PRKN and Sepsis: By tailoring interventions to specific molecular nodes—whether enhancing PINK1-Parkin flux in fibrosis, restoring SIRT3 activity in sepsis, or targeting FUNDC1 in hypoxia—researchers are pioneering strategies to break the cycle of mitochondrial dysfunction and inflammation.